详情页 - 首都医科大学宣武医院知识库

当前位置：首页 > 详情页

PD-1/PD-L1 Axis as a Potential Therapeutic Target for Multiple Sclerosis: A T Cell Perspective

102| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, China, [2]Department of Clinical Neuroscience, Karolinska Institutet, Solna, Sweden, [3]Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China, [4]Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden

出处：

DOI：

ISSN：

关键词： experimental autoimmune encephalomyelitis multiple sclerosis T cells programmed cell death ligand-1 programmed cell death protein-1

摘要：

The programmed cell death protein-1/programmed death ligand-1 (PD-1/PD-L1) axis is a widely studied immune checkpoint that modulates signaling pathways related to T cell activation. The use of PD-1/PD-L1 inhibitors is a promising immune therapy strategy for cancer patients. However, individuals treated with PD-1/PD-L1 inhibitors may develop immune-related adverse events due to excessive immune reactions. Multiple sclerosis (MS) is a chronic demyelinating and neurodegenerative disease of the central nervous system. T cells and the PD-1/PD-L1 axis play vital roles in the pathogenesis of MS. A better understanding of the complex relationship between the PD-1/PD-L1 axis and T cells may extend our knowledge of the molecular mechanisms and therapeutic approaches for MS. In this review, we summarize the most recent findings regarding the role of the PD-1/PD-L1 axis in MS and discuss the potential therapeutic strategies to modulate the expression of PD-1/PD-L1 in MS.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2020]版：

大类 | 2 区医学

小类 | 3 区神经科学

最新[2023]版：

大类 | 3 区医学

小类 | 3 区神经科学

JCR分区：

出版当年[2019]版：

Q2 NEUROSCIENCES

最新[2023]版：

Q2 NEUROSCIENCES

影响因子： 4.2 最新[2023版] 5.1 最新五年平均 3.921 出版当年[2019版] 4.438 出版当年五年平均 3.9 出版前一年[2018版] 5.505 出版后一年[2020版]

第一作者：

第一作者机构： [1]Department of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, China,

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]PD-L1 (Programmed Death Ligand 1) Regulates T-Cell Differentiation to Control Adaptive Venous Remodeling. [2]Autoreactive CD8+Central Memory T Cells Failed to Induce Experimental Autoimmune Encephalomyelitis [3]Proteome Profiling of Experimental Autoimmune Encephalomyelitis Mouse Model and the Effect of a SUMO E1 Inhibitor [4]Bushen Yisui Capsule ameliorates axonal injury in experimental autoimmune encephalomyelitis [5]Effect of Cordyceps sinensis on the Treatment of Experimental Autoimmune Encephalomyelitis: A Pilot Study on Mice Model [6]Epimedium flavonoids ameliorate experimental autoimmune encephalomyelitis in rats by modulating neuroinflammatory and neurotrophic responses [7]Zuogui pills for myelinolysis in a rat model of experimental autoimmune encephalomyelitis [8]Reactivated astrocytes as a possible source of oligodendrocyte precursors for remyelination in remitting phase of experimental autoimmune encephalomyelitis rats [9]The Regulatory Effect of Liuwei Dihuang Pills on Cytokines in Mice with Experimental Autoimmune Encephalomyelitis [10]Role of the PD-1/PD-L1 Signaling in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis: Recent Insights and Future Directions